Quentis, an immuno-oncology therapy developer based on research at Weill Cornell Medicine, has closed a round that included Taiho Pharmaceuticals and AbbVie Ventures.

Illumina and Mayo Clinic have reinvested in the genomics services platform, which has closed the first tranche of its series B round.

Partly based on Keio University research, CureApp has developed mobile apps to help treat nicotine addiction and fatty liver inflammation.

The Global University Venturing deal net rounds up all the latest smaller deals and tracks emerging companies accessing university funds.

The immuno-oncology therapy startup has completed a round that included Taiho Pharmaceuticals and AbbVie Ventures.

Adaptive drug technology developer Senti has completed a New Enterprise Associates-led series A round that included Amgen Ventures.

Existing investor GV returned to take part in a $110m round for the healthcare management software provider that included strategic partner Sun Life Financial.

The fund will invest up to $40m a year to back developers of drugs that will address the growing resistance of diseases to antibiotics.